Rallybio

📍 New Haven, United States🗓 Founded 2018👥 28 employees💰 Last funded Sep 2020
Biotechnology Research🌐 rallybio.com
Website LinkedIn
Rallybio (NASDAQ: RLYB) is a clinical-stage biotechnology company with a mission to develop and commercialize life-transforming therapies for patients with severe and rare diseases. Rallybio has built a pipeline of promising product candidates aimed at addressing diseases with unmet medical need in areas of complement dysregulation and hematology. The Company’s lead program, RLYB116, is a differentiated C5 inhibitor with the potential to treat diseases of complement dysregulation, with an initial focus on immune platelet transfusion refractoriness (PTR) and refractory antiphospholipid syndrome (APS). Rallybio’s pipeline also includes RLYB332, a preclinical long-acting matriptase-2 antibody for the treatment of diseases of iron overload. Rallybio is headquartered in New Haven, Connecticut.
3
Total investors
2
Early stage
0
Mid stage
0
Late stage
2018
Founded

Investors

3 investors
All
Early stage
Mid stage
Late stage
Investor geography1 country
United States
3
Investor activity2018–2020 · investors recorded per year
201812019120201
Recent (last 2y)Earlier
Frequently asked questions
Who invested in Rallybio?
Rallybio has 3 investors on record on gritt.io, including 2 early-stage backers.
When did Rallybio last raise funding?
The most recent investment in Rallybio recorded on gritt.io was in September 2020.
When was Rallybio founded?
Rallybio was founded in 2018.
What industry is Rallybio in?
Rallybio operates in Biotechnology Research. Find similar Biotechnology Research investors on gritt.io.
Where is Rallybio based?
Rallybio is headquartered in New Haven, United States.